PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting

In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:

• MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM
• RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary disease
• CARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogenetics
• STEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapy
• CAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MM

Presenter:

Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Link to full program:
https://bit.ly/4995nFA

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.